Abstract
A 66-year old man known case of metastatic castration resistant prostate cancer underwent successful 6 cycles treatment with 177Lu- prostate-specific membrane antigen. On the last post therapy whole body scan a new lesion in the skull was noted, suspected for disease progression. One week later, the patient complained from weakness of left upper extremity and brain magnetic resonance imaging revealed a brain tumor, confirmed as glioblastoma pathologically.
Keywords: PSMA, mCRPC, glioblastoma, prostate cancer
References
Norouzi G, Aghdam RA, Hashemifard H, Pirayesh E. Excellent response to lower dose of 177Lu-PSMA-617 in a metastatic castration-resistant prostate cancer patient with a transplanted kidney. Clin Nucl Med 2019;44:483-484.
Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. ESMO Open 2017;2:e000172.
Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol 2016;126:527-533.
Osman MM, Iravani A, Hicks RJ, Hofman MS. Detection of synchronous primary malignancies with 68Ga-labeled prostate-specific membrane antigen PET/CT in patients with prostate cancer: frequency in 764 patients. J Nucl Med 2017;58:1938-1942.
Grace S, Muzaffar R, Veerapong J, Alkaade S, Poddar N, Phillips N, Guzman M, Batanian J, Vogler C, Lai JP. Synchronous quadruple primary neoplasms: glioblastoma, neuroendocrine tumor, schwannoma and sessile serrated adenoma in a patient with history of prostate cancer. Anticancer Res 2015;35:2121-2127.
Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-446.
Salas Fragomeni RA, Amir T, Sheikhbahaei S, Harvey SC, Javadi MS, Solnes LB, Kiess AP, Allaf ME, Pomper MG, Gorin MA, Rowe SP. Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms. J Nucl Med 2018;59:871-877.
